Jim Wilson (WuXi Global Forum at JPM20)
March 15, 2022 09:12 AM EDTUpdated March 18, 01:39 PM
People
R&D

Roiled by se­nior-lev­el ex­its, Jim Wil­son’s Pas­sage Bio re­trench­es, chop­ping back on staff as it ex­tends cash run­way

John Carroll

Editor & Founder

A lit­tle more than 3 years af­ter Penn’s Jim Wil­son and the late Tachi Ya­ma­da her­ald­ed the launch of their gene ther­a­py up­start Pas­sage …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times